RVI RUBEOLA VIRUS IMMUNOMODULATOR. RVI acts to modify the immune and inflammatory responses to alleviate chronic myofascial inflammation (myositis) and its associated problems in the equine. RVI is an inactivated rubeola virus combined with histamine phosphate in physiological saline. Contains phenol as a preservative. Each 2 mL dose contains 0.1 mcg of neomycin.

Dosage and Administration: Inject 2 mL subcutaneously in the neck once a day regardless of weight or age for three (3) to six (6) days or until the desired clinical condition is observed. In severe cases, a daily injection may be required until the horse recovers. Maintenance doses and frequency will depend upon the individual animal but may vary from one (1) dose every other day to one (1) dose a week or even every two (2) weeks. Care should be exercised to ensure that the injection is delivered subcutaneously.

Precaution(s): Store at 35°-45°F (2°-7°C). Protect from freezing.

Caution(s): Rare transient local reactions may occur at the injection site but should subside within 24 hours. For veterinary use only.

Warning(s): Not for use in horses intended for food.

 

12 ml Vial

The use of Rubeola Virus Immunomodulator as a Practical Application For the Elimination of Musculo-Skeletal Pain in the Equine Athlete David Nichols, DVM, and Randall D. Robbins, Ph.D. Introduction Rubeola Virus Immunomodulator (RVI) is a relatively new product available for the treatment of myositis in horses.

 

The rubeola virus has been shown to influence many cells ofthe immune system including monocytes, B lymphocytes, T helper lymphocytes and T suppression lymphocytes. The mode of action of this product utilizes the theory that when a control mechanism of an animal’s immune system becomes unregulated, cellular damage can occur or be exaggerated from the same system attempting to protect it (Whitesides,et al. 1992). Developers of this product theorize that RVI functions by providing an appropriate molecule that can modify the immune system in a manner that allows the re-establishment of proper control mechanisms.

 

Therefore, clinical myositis cases exhibit improvement of reduced lumbar myofascial inflammation not through the direct action of the drug, but by enhancing the animal’s immune system to naturally reverse the inflammatory process. The use of immunomodulators such as RVI to modulate the immune system, which in turn targets specific biological cells or systems that affect healing responses, creates many possibilities in the treatment of disease or injury.

 

RVI specifically targets the musculo-skeletal system, effectively reducing inflammation and pain. Reports from field clinical investigations indicate that RVI has been effective in treating various problems of both horses and dogs. In field clinical investigations, RVI has produced positive results in dogs suffering from chronic intervertebral disc syndrome as well as spondylosis deformans (Polley, 1993). Horses subjected to the stresses of intense exercise programs and performance schedules are prone to muscle and skeletal injury.

 

These horses respond rapidly to RVI treatment programs. Often, horses that display myofascial pain in the lumbar regions concurrently exhibit lameness in the lower limbs. Lameness in the lower extremities of often accompanies by myofascial or bursal inflammation directly or indirectly related to injuries of the tarsal-metatarsal regions.

 

Therefore, the primary objective of this study was to determine the effects of extended RVI treatment programs on performance horses prone to tarsal-metatarsal injuries currently exhibiting bursal inflammation and tendonitis with or without accompanying myofascial pain in the lumbar region.

 

12 ml vial